{"nctId":"NCT00195676","briefTitle":"Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis","startDateStruct":{"date":"2004-05"},"conditions":["Psoriasis"],"count":1469,"armGroups":[{"label":"Adalimumab","type":"OTHER","interventionNames":["Drug: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.\n* Subjects who met the requirements from previous adalimumab psoriasis study participation.\n\nExclusion Criteria:\n\n* Subject considered by the Investigator, for any reason, to be an unsuitable candidate for the study.\n* Female subject who was pregnant or breast-feeding or considering becoming pregnant.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 60","description":"The Physician's Global Assessment \\[PGA\\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 120","description":"The Physician's Global Assessment \\[PGA\\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R","description":"The Physician's Global Assessment \\[PGA\\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 60","description":"Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Achieved a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 120","description":"Psoriasis Area and Severity Index (PASI) scores were calculated from assessments at 4 designated anatomical sites (head, upper extremities, trunk, lower extremities) using both severity and area subscores (i.e., degree of and amount of psoriatic involvement per site). PASI scores range from 0.0 (best) to 72.0 (worst), with the highest score representing complete erythroderma of the severest degree. Positive percent decreases indicate improvement, with the best improvement being 100%. A PASI 75 response was at least a 75% reduction in PASI score from baseline PASI score of the initial study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Relapse in Period W","description":"Relapse of psoriasis was defined as a Physician's Global Assessment (assessment of overall lesion severity) score of greater than or equal to 3 (3=moderate; 4=severe; 5=very severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Period R Modified Intent-to-Treat Participants Who Relapsed in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R","description":"The Physician's Global Assessment \\[PGA\\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Period R Modified Intent-to-Treat Participants Who Did Not Relapse in Period W and Subsequently Had a Physician's Global Assessment of Clear or Minimal at Week 16 of Period R","description":"The Physician's Global Assessment \\[PGA\\] was scored by the physician using a 6-point scale (0-5) for the degree of overall lesion severity, where 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, and 5 = very severe. Subjects with a PGA of Clear or Minimal overall lesion severity had scores of 0 or 1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":189,"n":1468},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Hypertension","Arthralgia"]}}}